Archive: Company News
Company News: Curetis to Present at Solebury Trout European Biotech Investor Day in NYC
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that its CEO Oliver Schacht, PhD, will present at the European Biotech Investor Day in New York City, NY, USA, on Thursday, August 1, 2019, at 4pm EST. The life science-focused conference is organized by Solebury Trout and sponsored by Goodwin LLC, Deutsche Bank, H.C. Wainwright and Nasdaq and will be held at offices of Goodwin LLC in the New York Times building. Read more…
Company News: Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens
– Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% and overall weighted average specificity of up to 98.4%
– Unyvero provides results after approximately five hours, compared to an average of several days for standard-of-care methods
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration for its Unyvero LRT Lower Respiratory Tract Cartridge for use with BAL (bronchoalveolar lavage) specimens. Read more…
Company News: BellaSeno’s Design and Manufacturing Processes Fully ISO 13485 Certified
– Company transitions from research to manufacturing stage, raises an additional EUR 1 million to conduct clinical trial
– Among the first medtech companies worldwide to offer integrated contract manufacturing of additively produced implants under ISO standards
BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technology, today announced it obtained full ISO 13485 certification for its design and additive manufacturing processes, ranging from the concept and prototype to the production of novel, non-silicone-based absorbable implants. Read more…
Company News: Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing
— Patent broadly covers genetic biomarkers and biomarker combinations indicating antibiotic resistance
— First of eleven similar patents filed covering various pathogen/drug combinations
— Strengthens unique position of ARESdb, Ares Genetics’ knowledgebase of antimicrobial resistance genetics
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly owned subsidiary Ares Genetics GmbH has received a notification by the European Patent Office (EPO) on the decision to grant the European Patent No. 3 099 813 titled “Genetic Resistance Testing”. Read more…